@article{616c82cab8d144c1a492e7c3ba11dfd2,
title = "The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease",
abstract = "Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.",
keywords = "Atherosclerosis, CD40, CD40L, Cardiovascular disease, Immune checkpoint proteins, Inflammation",
author = "Bosmans, {Laura A.} and Lena Bosch and Kusters, {Pascal J. H.} and Esther Lutgens and Seijkens, {Tom T. P.}",
note = "Funding Information: This study was funded by the Netherlands Heart Institute (Young@Heart grant to T.T.P.S.), THE Amsterdam Cardiovascular Sciences (MD/PhD grant to T.T.P.S.), the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands, Organization for Health Research and Development and the Royal Netherlands Academy of Sciences for the GENIUS-II project {\textquoteleft}Generating the best evidence-based pharmaceutical targets for atherosclerosis-II{\textquoteright} (CVON2018–19). This study was also supported by the Netherlands Organization for Scientific Research (NWO) (VICI grant 016.130.676 to E.L.), the European Union (H2020-PHC-2015–667673, REPROGRAM to E.L.), the European Research Council (ERC consolidator grant CD40-INN 681492 to E.L.) and the German Science Foundation (DFG, CRC1123, project A5). Acknowledgements Funding Information: We would like to thank Servier for the artwork used in the figures (Servier Medical Art https:// smart.servier.com). Publisher Copyright: {\textcopyright} 2020, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = feb,
doi = "https://doi.org/10.1007/s12265-020-09994-3",
language = "English",
volume = "14",
pages = "13--22",
journal = "Journal of cardiovascular translational research",
issn = "1937-5387",
publisher = "Springer New York",
number = "1",
}